News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Human Genome Sciences, Inc. Rejects GlaxoSmithKline’s $2.6 Billion Bid, Seeks Higher Offers
April 19, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Human Genome Sciences Inc said it had rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector that has been swept by M&A recently.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Mergers & acquisitions
Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition
September 22, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Novartis Looking for Constructive Ways To Bring Down Drug Costs in US
September 22, 2025
·
2 min read
·
Tristan Manalac
IPOs
MapLight Keeps Biopharma’s IPO Flame Alight To Advance Alzheimer’s, Schizophrenia Drugs
September 22, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand
September 19, 2025
·
2 min read
·
Annalee Armstrong
